A real-world study on persistence with ofatumumab in Canadian patients with multiple sclerosis

In multiple sclerosis, disease-modifying therapies aim to reduce relapse rate and slow disease progression. An important component of successful disease control is treatment persistence, which is the time a patient remains on a therapy. The primary objective of this study was to examine persistence with ofatumumab in a real-world setting.

This was a retrospective cohort study using data from the Patient Support Program (clinicaltrials.gov number NCT06854341). Adults diagnosed with relapsing remitting multiple sclerosis who initiated ofatumumab were included. Persistence, defined as the number of days from ofatumumab initiation until discontinuation, was assessed from April 2021 to May 2024. Ofatumumab persistence was quantified by Kaplan-Meier estimates for discontinuation probabilities with corresponding 95% confidence intervals at 12, 24 and 36 months. Secondary objectives included a descriptive analysis of patients' baseline demographic and clinical characteristics, and their association with discontinuation.

The PSP included a total of 6377 patients, of which 5436 patients met the inclusion criteria and had information to assess discontinuation. Persistence probability with ofatumumab was 96.94% at 12-months, 95.02% at 24-months, and 92.26% at 36-months post index. During this period, 167 patients (3.1%) discontinued ofatumumab. The most common reasons for discontinuation included side effects (0.9%), trying to conceive/pregnancy (0.5%), and patient request (0.5%).

This study provides insights into real-world ofatumumab utilization among patients with multiple sclerosis and demonstrates that persistence with ofatumumab remained high over 3 years. These results complement data from controlled clinical trials and suggest that patients persist with ofatumumab.